MX2014006182A - Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. - Google Patents
Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr.Info
- Publication number
- MX2014006182A MX2014006182A MX2014006182A MX2014006182A MX2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A
- Authority
- MX
- Mexico
- Prior art keywords
- egfr inhibitor
- treatment
- patient
- predicting responsiveness
- egfr
- Prior art date
Links
- 229940121647 egfr inhibitor Drugs 0.000 title abstract 3
- 230000004043 responsiveness Effects 0.000 title 1
- 102000001301 EGF receptor Human genes 0.000 abstract 2
- 108060006698 EGF receptor Proteins 0.000 abstract 2
- 108091070395 Homo sapiens miR-31 stem-loop Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306568 | 2011-11-25 | ||
| EP12306042 | 2012-08-31 | ||
| PCT/EP2012/073535 WO2013076282A1 (en) | 2011-11-25 | 2012-11-23 | A method for predicting responsiveness to a treatment with an egfr inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014006182A true MX2014006182A (es) | 2014-12-08 |
Family
ID=47297187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014006182A MX2014006182A (es) | 2011-11-25 | 2012-11-23 | Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10400284B2 (enExample) |
| EP (1) | EP2783017B1 (enExample) |
| JP (1) | JP6342329B2 (enExample) |
| KR (1) | KR20140104419A (enExample) |
| CN (1) | CN104160038B (enExample) |
| AU (1) | AU2012342397B2 (enExample) |
| BR (1) | BR112014012495A2 (enExample) |
| CA (1) | CA2856594A1 (enExample) |
| MX (1) | MX2014006182A (enExample) |
| WO (1) | WO2013076282A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3074530A1 (en) * | 2013-11-26 | 2016-10-05 | Integragen | A method for predicting responsiveness to a treatment with an egfr inhibitor |
| KR101622454B1 (ko) | 2014-03-04 | 2016-05-18 | 연세대학교 산학협력단 | Egfr 티로신 키나아제 억제제에 대한 항암 치료 반응 예측 마커 |
| ES2823756T3 (es) * | 2014-04-16 | 2021-05-10 | Signal Pharm Llc | Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR |
| EP3000895A1 (en) * | 2014-09-26 | 2016-03-30 | Integragen | A method for predicting responsiveness to a treatment with an EGFR inhibitor |
| CN107850599B (zh) * | 2015-07-23 | 2021-02-09 | 新加坡国立大学 | Wbp2与her2作为共预后因子对患者分层以进行治疗 |
| WO2017187937A1 (ja) * | 2016-04-28 | 2017-11-02 | デンカ株式会社 | 上皮性細胞成長因子受容体阻害剤に対する癌細胞の耐性を判定する方法 |
| JP7564122B2 (ja) * | 2019-03-29 | 2024-10-08 | ラクテン・メディカル，インコーポレイテッド | 光免疫療法のための方法および関連バイオマーカー |
| KR102251864B1 (ko) * | 2019-10-18 | 2021-05-14 | 지니너스 주식회사 | miR-320c를 유효성분으로 포함하는 백금계 항암제에 대한 삼중음성유방암 환자의 약물 반응성 예측용 바이오마커 조성물 |
| CN111798918A (zh) * | 2020-05-28 | 2020-10-20 | 中山大学孙逸仙纪念医院 | 一种免疫治疗疗效预测的血肿瘤突变算法及其构建方法 |
| CN111863159B (zh) * | 2020-06-01 | 2022-02-25 | 中山大学孙逸仙纪念医院 | 一种肿瘤免疫治疗疗效预测的列线图模型的建立方法 |
| JP2025507824A (ja) * | 2022-03-01 | 2025-03-21 | クラウン バイオサイエンス （スーチョウ） インコーポレイテッド | がん患者におけるセツキシマブ感受性を決定するための方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100523216C (zh) | 2001-03-02 | 2009-08-05 | 匹兹堡大学 | Pcr方法 |
| JP2011500086A (ja) * | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | 完全ヒト抗ｖｅｇｆ抗体および使用方法 |
| WO2009080437A1 (en) | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| WO2010015538A2 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
| US20120095030A1 (en) * | 2009-04-17 | 2012-04-19 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors |
| EP2521555B1 (en) * | 2009-11-24 | 2016-09-28 | The University Of Western Australia | Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors |
| AU2011246976B2 (en) * | 2010-04-29 | 2016-01-28 | Allarity Therapeutics Europe ApS | Methods and devices for predicting treatment efficacy |
-
2012
- 2012-11-23 CA CA2856594A patent/CA2856594A1/en not_active Abandoned
- 2012-11-23 AU AU2012342397A patent/AU2012342397B2/en not_active Ceased
- 2012-11-23 CN CN201280067832.4A patent/CN104160038B/zh not_active Expired - Fee Related
- 2012-11-23 MX MX2014006182A patent/MX2014006182A/es unknown
- 2012-11-23 EP EP12797814.6A patent/EP2783017B1/en not_active Not-in-force
- 2012-11-23 BR BR112014012495A patent/BR112014012495A2/pt active Search and Examination
- 2012-11-23 JP JP2014542865A patent/JP6342329B2/ja not_active Expired - Fee Related
- 2012-11-23 US US14/360,311 patent/US10400284B2/en not_active Expired - Fee Related
- 2012-11-23 KR KR1020147014013A patent/KR20140104419A/ko not_active Ceased
- 2012-11-23 WO PCT/EP2012/073535 patent/WO2013076282A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140104419A (ko) | 2014-08-28 |
| CN104160038A (zh) | 2014-11-19 |
| AU2012342397A1 (en) | 2014-06-12 |
| JP6342329B2 (ja) | 2018-06-13 |
| US10400284B2 (en) | 2019-09-03 |
| BR112014012495A2 (pt) | 2017-06-06 |
| CN104160038B (zh) | 2018-06-12 |
| EP2783017A1 (en) | 2014-10-01 |
| JP2014533960A (ja) | 2014-12-18 |
| AU2012342397B2 (en) | 2018-04-05 |
| CA2856594A1 (en) | 2013-05-30 |
| US20140370029A1 (en) | 2014-12-18 |
| EP2783017B1 (en) | 2018-12-26 |
| WO2013076282A1 (en) | 2013-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014006182A (es) | Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. | |
| LTPA2019503I1 (lt) | Modifikuotų T ląstelių, turinčių chimerinų antigeno receptorių, panaudojimas vėžio gydymui | |
| WO2013009655A3 (en) | Uses of labeled hsp90 inhibitors | |
| IL233019A0 (en) | System and method for locating sources of biological arrhythmias | |
| EP2770090A4 (en) | METHOD FOR PRODUCING A NUCLEIC ACID LIBRARY AND USES THEREOF AND KITS THEREFOR | |
| EP2818108A4 (en) | METHOD FOR DETERMINING GLUCOSE CONCENTRATION IN HUMAN BLOOD | |
| IN2012DN02485A (enExample) | ||
| PT2683384E (pt) | Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona | |
| MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
| WO2012106718A3 (en) | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment | |
| EA201490265A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| EP2788773A4 (en) | DEVICE, SYSTEM AND METHOD FOR IDENTIFYING CIRCULATING TUMOR CELLS | |
| WO2011146568A8 (en) | Predicting response to a her inhibitor | |
| WO2011094335A3 (en) | Microrna signatures predicting responsiveness to anti-her2 therapy | |
| WO2013040436A3 (en) | Esx-mediated transcription modulators and related methods | |
| UA111075C2 (uk) | Триазолопіридинові сполуки як інгібітори кінази рім | |
| EP2911056A4 (en) | METHOD FOR RESTRICTING THE CONSUMPTION OF A STORAGE SYSTEM AND MEMORY CONTROL | |
| EA201590773A1 (ru) | Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf альфа) | |
| MX348655B (es) | Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer. | |
| MX354270B (es) | Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. . | |
| PH12013502530A1 (en) | Glioblastoma inhibiting compounds and their use | |
| EP2568459A4 (en) | TRAFFIC CONTROL SYSTEM AND METHOD | |
| IL232493A0 (en) | A method for quantifying cancer treatment | |
| MX2016006782A (es) | Un metodo para predecir la capacidad de respuesta a un tratamiento con un inhibidor del egfr. | |
| GB201312965D0 (en) | Stem cell factor inhibitor |